{"id":973,"date":"2020-10-18T11:30:22","date_gmt":"2020-10-18T08:30:22","guid":{"rendered":"http:\/\/demo.safirtema.com\/anka\/?p=973"},"modified":"2020-10-18T12:47:53","modified_gmt":"2020-10-18T09:47:53","slug":"yerli-asinin-uretildigi-fabrikada-son-durum-her-sey-yolunda-giderse-mayista-hazir","status":"publish","type":"post","link":"https:\/\/balikesirobjektif.com\/index.php\/2020\/10\/18\/yerli-asinin-uretildigi-fabrikada-son-durum-her-sey-yolunda-giderse-mayista-hazir\/","title":{"rendered":"Yerli a\u015f\u0131n\u0131n \u00fcretildi\u011fi fabrikada son durum: “Her \u015fey yolunda giderse May\u0131s’ta haz\u0131r”"},"content":{"rendered":"

Sa\u011fl\u0131k Bakan\u0131 Dr. Fahrettin Koca, ilk kez ge\u00e7ti\u011fimiz hafta Tekirda\u011f<\/strong>\u2019daki Ko\u00e7ak Farma Tesisleri\u2019nde, Covid-19<\/strong> yerli a\u015f\u0131 \u00e7al\u0131\u015fmalar\u0131n\u0131n y\u00fcr\u00fct\u00fcld\u00fc\u011f\u00fc laboratuvarda incelemede bulunarak Cumhurba\u015fkan\u0131 Recep Tayyip Erdo\u011fan ile g\u00f6r\u00fcnt\u00fcl\u00fc g\u00f6r\u00fc\u015fme yapm\u0131\u015f ve \u00e7al\u0131\u015fmalara ili\u015fkin bilgi vermi\u015fti.<\/p>\n

Bakan Koca, daha sonra m\u00fcjdeyi vererek Faz 1 denemelerine 44 g\u00f6n\u00fcll\u00fc \u00fczerinde ba\u015flanaca\u011f\u0131n\u0131 a\u00e7\u0131klam\u0131\u015ft\u0131. Yar\u0131m as\u0131rl\u0131k yerli firma Ko\u00e7ak Farma\u2019n\u0131n Genel M\u00fcd\u00fcr\u00fc ve CEO’su \u0130\u00e7 Hastal\u0131klar\u0131 Uzman\u0131 Dr. Hakan Ko\u00e7ak, pre-klinik yani hayvan deneyleri tamamlanan ve art\u0131k insanlar \u00fczerinde klinik ara\u015ft\u0131rmalar\u0131n ba\u015flat\u0131ld\u0131\u011f\u0131 Faz 1 a\u015famas\u0131na gelen yerli a\u015f\u0131yla ilgili merak edilenleri anlatt\u0131.<\/p>\n

Y\u00fcksek g\u00fcvenlikli BSL-3 laboratuvar\u0131na sahip Ko\u00e7ak Farma\u2019n\u0131n \u00c7erkezk\u00f6y\u2019deki 140 bin metrekarelik tesislerinde, pandemi d\u00f6neminde ikinci bir giri\u015fim daha yap\u0131ld\u0131 ve Covid a\u015f\u0131s\u0131n\u0131n \u00fcretimi i\u00e7in birka\u00e7 ay i\u00e7inde yakla\u015f\u0131k 20 milyon euro\u2019luk yat\u0131r\u0131mla ikinci bir BSL-3 laboratuvar\u0131 daha kurularak akreditasyonu tamamland\u0131. Dr. Ko\u00e7ak, laboratuvarlar\u0131n, geli\u015ftirilen di\u011fer yerli a\u015f\u0131lar ve talep olursa yabanc\u0131 a\u015f\u0131lar\u0131n \u00fcretimini de yapabilecek kapasiteye sahip oldu\u011funu vurgulad\u0131.<\/p>\n

\u201cHER \u015eEY YOLUNDA G\u0130DERSE MAYIS\u2019TA HAZIR”<\/strong><\/p>\n

Dr. Hakan Ko\u00e7ak, yakla\u015f\u0131k 100 bilim insan\u0131n\u0131n g\u00f6rev yapt\u0131\u011f\u0131 Ko\u00e7ak Farma Ar-Ge departman\u0131nda aylard\u0131r \u00fczerinde \u00e7al\u0131\u015f\u0131lan Covid-19 a\u015f\u0131s\u0131<\/strong>n\u0131n, inaktif a\u015f\u0131 olarak bilinen \u00f6l\u00fc vir\u00fcs a\u015f\u0131s\u0131 olarak dizayn edildi\u011fini s\u00f6yleyerek, \u201c\u0130naktif a\u015f\u0131lar\u0131n \u00f6zelli\u011fi, uzun y\u0131llard\u0131r a\u015f\u0131 \u00fcretiminde kullan\u0131lan bir teknoloji olmas\u0131. Yine burada kullan\u0131lan h\u00fccre hatlar\u0131n\u0131n da daha \u00f6nceki a\u015f\u0131larda kullan\u0131lan ve iyi tan\u0131mlanm\u0131\u015f h\u00fccre hatlar\u0131ndan olu\u015fmas\u0131… Bu a\u00e7\u0131dan bizim i\u00e7in bilinirli\u011fi fazla, daha g\u00fcvenli diyebilece\u011fimiz a\u015f\u0131lard\u0131r inaktif a\u015f\u0131lar. Buzdolab\u0131nda 2 ila 8 derecede muhafaza edilebilir. O y\u00fczden hem so\u011fuk zincirin korunmas\u0131, hem ta\u015f\u0131nmas\u0131, hem de \u00fcretimi ve uygulamas\u0131 daha kolay a\u015f\u0131lard\u0131r. D\u00fcnya n\u00fcfusu 7,8 milyar civar\u0131nda. Dolay\u0131s\u0131yla \u00e7ok say\u0131da a\u015f\u0131ya ihtiyac\u0131m\u0131z var. Bu nedenle de a\u015f\u0131n\u0131n s\u00fcratle \u00fcretilip insanlara ula\u015ft\u0131r\u0131lmas\u0131 \u00e7ok b\u00fcy\u00fck \u00f6nem ta\u015f\u0131yor. Yani bunu en k\u0131sa s\u00fcrede yapmam\u0131z laz\u0131m. Her \u015fey planland\u0131\u011f\u0131 \u015fekilde ilerlerse, May\u0131s ay\u0131 gibi a\u015f\u0131n\u0131n haz\u0131r olaca\u011f\u0131n\u0131 d\u00fc\u015f\u00fcn\u00fcyoruz. Bizim a\u015f\u0131 \u00fcretme kapasitemiz ayl\u0131k 20 milyon doz. Tabii ki bu a\u015f\u0131 \u00f6ncelikle \u00fclkemizdeki insanlar\u0131m\u0131z i\u00e7in kullan\u0131lacak. Ama Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131m\u0131z\u0131n da bu y\u00f6nde bir \u00e7al\u0131\u015fmas\u0131 olursa, di\u011fer \u00fclkelere de bu a\u015f\u0131y\u0131 ihra\u00e7 etme imkan\u0131na sahibiz” dedi.<\/p>\n

<\/div>\n

\u2018CHALLENGE\u2019 TEST\u0130N\u0130 BA\u015eARIYLA GE\u00c7T\u0130, \u015e\u0130MD\u0130 SIRA G\u00d6N\u00dcLL\u00dc \u0130NSANLARDA<\/strong><\/p>\n

Geli\u015ftirdikleri a\u015f\u0131n\u0131n, pre-klinik olarak adland\u0131r\u0131lan hayvan deneyleri sonu\u00e7lar\u0131ndan da bahseden Dr. Ko\u00e7ak, a\u015f\u0131y\u0131 Faz 1 g\u00f6n\u00fcll\u00fc insan denemelerine g\u00f6t\u00fcren s\u00fcre\u00e7 hakk\u0131nda ise \u015fu \u00f6nemli bilgileri verdi:<\/p>\n

\u201cBizim yapt\u0131\u011f\u0131m\u0131z hayvan deneylerinde (transjenik) fareler kullan\u0131ld\u0131. 60 farede yapt\u0131k denemeleri. A\u015f\u0131 uygulad\u0131\u011f\u0131m\u0131z farelerde y\u00fcksek antikor titreleri elde ettik. Yani hastal\u0131\u011fa kar\u015f\u0131 y\u00fcksek bir ba\u011f\u0131\u015f\u0131kl\u0131k olu\u015ftu. Pre-klinik \u00e7al\u0131\u015fmalarda bir k\u0131s\u0131m fare a\u015f\u0131land\u0131ktan sonra Covid-19 vir\u00fcs\u00fc ile enfekte edildi. Bir k\u0131sm\u0131na da a\u015f\u0131 yapmadan vir\u00fcs verildi. A\u015f\u0131 yap\u0131lan farelerde herhangi bir hastal\u0131k belirtisi g\u00f6r\u00fclmezken, a\u015f\u0131 yap\u0131lmayan farelerin bir k\u0131sm\u0131 \u00f6ld\u00fc; hayatta kalanlar\u0131n da akci\u011ferlerinde ve di\u011fer organlar\u0131nda hastal\u0131k belirtileri tespit edildi. Biz bu testlere \u2018Challenge\u2019 testi diyoruz. Challenge testlerimiz de ba\u015far\u0131yla sonu\u00e7land\u0131. Yine bu hayvanlarda yapt\u0131\u011f\u0131m\u0131z toksikolojik \u00e7al\u0131\u015fmalarda, a\u015f\u0131n\u0131n herhangi bir toksik, yani yan etkisinin olmad\u0131\u011f\u0131 tespit edildi.”<\/p>\n

21 G\u00dcN ARAYLA \u0130K\u0130 DOZ YAPILACAK, \u0130LK DOZDAN 42 G\u00dcN SONRA ANT\u0130KOR BAKILACAK<\/strong><\/p>\n

Hayvan deneylerinden al\u0131nan olumlu veriler sonucu insan faz \u00e7al\u0131\u015fmalar\u0131na ge\u00e7ilebildi\u011fine i\u015faret eden Dr. Ko\u00e7ak, \u015f\u00f6yle devam etti:<\/p>\n

\u201c\u0130nsan faz \u00e7al\u0131\u015fmalar\u0131 da \u00fc\u00e7 a\u015famadan olu\u015fuyor. Faz 1-2 ve 3. Bizim de ba\u015flayaca\u011f\u0131m\u0131z Faz 1\u2019de, \u00f6nce az say\u0131da g\u00f6n\u00fcll\u00fcler \u00fczerinde klinik deneme yap\u0131lacak. Yakla\u015f\u0131k 40-50 g\u00f6n\u00fcll\u00fc \u00fczerinde yap\u0131lan bir \u00e7al\u0131\u015fmad\u0131r bu. \u00d6ncelikle 18-60 ya\u015f aras\u0131nda sa\u011fl\u0131kl\u0131 bireyler olmas\u0131 gerekir. Daha \u00f6nce Covid-19 enfeksiyonu ge\u00e7irmemi\u015f olmas\u0131 da laz\u0131m. Bu y\u00f6nden tetkikleri yap\u0131ld\u0131ktan sonra ve belli bir s\u00fcre, yakla\u015f\u0131k 5 g\u00fcn kadar karantinada tutulduktan sonra \u00e7al\u0131\u015fmaya al\u0131nacak g\u00f6n\u00fcll\u00fcler. Faz 1\u2019de ilk planda a\u015f\u0131n\u0131n olas\u0131 yan etkileri g\u00f6zlemlenir. \u0130lk sonu\u00e7lar olumlu oldu\u011funda, Faz 1 ve Faz 2\u2019ye ayn\u0131 anda da devam edilebilir. Faz 2\u2019de biraz daha geni\u015f bir g\u00f6n\u00fcll\u00fc grubuna uygulan\u0131r a\u015f\u0131, 200 ila 400 ki\u015fi gibi. Burada da yine a\u015f\u0131n\u0131n etkinlik ve g\u00fcvenli\u011finin yan\u0131 s\u0131ra, ka\u00e7 doz uygulanaca\u011f\u0131 tespit edilir. Bizim a\u015f\u0131m\u0131z\u0131n uygulanma \u015fekli iki doz \u015feklinde. 21 g\u00fcn arayla yap\u0131l\u0131yor. \u0130lk a\u015f\u0131n\u0131n yap\u0131lmas\u0131ndan 21 g\u00fcn sonra bir de rapel doz dedi\u011fimiz peki\u015ftirme dozu yap\u0131yoruz. Bundan da 21 g\u00fcn sonra, kandaki antikor d\u00fczeylerine bak\u0131yoruz. Faz 2\u2019de bu dozlar\u0131n hangisinin daha uygun d\u00fczeyde antikor olu\u015fturdu\u011fu ve hangi periyotta yap\u0131ld\u0131\u011f\u0131nda daha etkili oldu\u011fu ile ilgili \u00e7al\u0131\u015fmalar da y\u00fcr\u00fct\u00fcl\u00fcr. Bunlar\u0131n sonu\u00e7lar\u0131 da istenen d\u00fczeyde olursa Faz 3 a\u015famas\u0131na ge\u00e7ilecek.”<\/p>\n

<\/div>\n

\u201cB\u0130Z DE K\u00dcRESEL \u00d6L\u00c7EKTE FAZ 3 \u00c7ALI\u015eMALARI PLANLAYAB\u0130L\u0130R\u0130Z”<\/strong><\/p>\n

A\u015f\u0131n\u0131n piyasaya \u00e7\u0131kmas\u0131ndan \u00f6nceki son d\u00fczl\u00fck olarak da bilinen Faz 3 \u00e7al\u0131\u015fmalar\u0131n\u0131n ise art\u0131k binlerce g\u00f6n\u00fcll\u00fc \u00fczerinde yap\u0131ld\u0131\u011f\u0131na i\u015faret eden Dr. Ko\u00e7ak, burada \u00fclkeler aras\u0131 i\u015fbirli\u011finin de devreye girebilece\u011fini s\u00f6yleyerek \u015fu a\u00e7\u0131klamalarda bulundu:<\/p>\n

\u201cBu a\u015famada g\u00f6n\u00fcll\u00fcler, ilk etapta risk durumlar\u0131 g\u00f6zetilerek belirlenir. Mesela sa\u011fl\u0131k personelinin Covid-19 enfeksiyonuna yakalanma riski \u00e7ok y\u00fcksek oldu\u011fu i\u00e7in, onlara \u00f6ncelik tan\u0131n\u0131yor Faz 3\u2019de. Ayr\u0131ca bu a\u015famada bir grup g\u00f6n\u00fcll\u00fcye a\u015f\u0131 uygulan\u0131rken, bir gruba da plasebo verilerek kontrol grubu olu\u015fturulur. Binlerce g\u00f6n\u00fcll\u00fc hem T\u00fcrkiye’den, hem de di\u011fer \u00fclkelerden belirlenebilir. Burada \u00f6nemli olan, \u00fclkelerin i\u015fbirli\u011fi ve a\u015f\u0131ya olan talebi. Nitekim \u00c7in’de geli\u015ftirilen bir a\u015f\u0131n\u0131n \u015fu anda T\u00fcrkiye’de de devam eden Faz 3 \u00e7al\u0131\u015fmalar\u0131 var. Ba\u015fka \u00fclkelerde g\u00f6n\u00fcll\u00fc denemesi yap\u0131lmas\u0131n\u0131n nedenlerinden birisi de, \u015fayet o \u00fclkede de bu a\u015f\u0131n\u0131n kullan\u0131lmas\u0131 d\u00fc\u015f\u00fcn\u00fcl\u00fcyorsa, bu sayede a\u015f\u0131n\u0131n o \u00fclkenin insanlar\u0131nda da etkili olup olmad\u0131\u011f\u0131 de\u011ferlendiriliyor. Biz de talep oldu\u011fu takdirde geli\u015ftirdi\u011fimiz a\u015f\u0131n\u0131n Faz 3 a\u015famas\u0131nda ba\u015fka \u00fclkelerde g\u00f6n\u00fcll\u00fc klinik denemeleri ger\u00e7ekle\u015ftirebiliriz.”<\/p>\n

<\/div>\n

\u201c\u00dcRET\u0130M KAPAS\u0130TEM\u0130Z Y\u00dcKSEK, DI\u015e PAZARA DA \u0130HRA\u00c7 EDEB\u0130L\u0130R\u0130Z”<\/strong><\/p>\n

A\u015f\u0131 piyasaya \u00e7\u0131kt\u0131\u011f\u0131nda ilk hedeflerinin T\u00fcrkiye\u2019deki ihtiyac\u0131n kar\u015f\u0131lanmas\u0131 oldu\u011funun alt\u0131n\u0131 \u00e7izen Dr Hakan Ko\u00e7ak, T\u00fcrkiye\u2019nin yakla\u015f\u0131k 3 y\u0131l \u00f6nce aralar\u0131nda \u0130svi\u00e7re, ABD, \u0130ngiltere, \u0130rlanda, Almanya, Kanada, Japonya ve Avusturalya’n\u0131n da yer ald\u0131\u011f\u0131 \u201cUluslararas\u0131 \u0130la\u00e7 Denetim Birli\u011fi (PIC\/S)\u00f6 \u00fcyeli\u011fine kabul edildi\u011fini de vurgulayarak, \u201cBuraya \u00fcye \u00fclkeler, ila\u00e7 veya a\u015f\u0131larda birbirlerinin ruhsatlar\u0131n\u0131 ve denetimlerini tan\u0131yabiliyor. Bu \u00fcyelik, yerli a\u015f\u0131n\u0131n ihracat\u0131nda da \u00f6nemli bir rol oynayacak. Onun d\u0131\u015f\u0131nda, yurtd\u0131\u015f\u0131na a\u015f\u0131 ihracat\u0131 yapabilmeniz i\u00e7in \u00e7al\u0131\u015fma sonu\u00e7lar\u0131n\u0131z\u0131 i\u00e7eren bir dosya haz\u0131rlay\u0131p mesela Avrupa Birli\u011fi’nde EMA, Amerika’da FDA gibi otoritelere sunman\u0131z gerekiyor. Dosyan\u0131z incelenip uygun bulunursa, a\u015f\u0131 ihracat\u0131 imkan\u0131n\u0131z g\u00fc\u00e7leniyor” dedi.<\/p>\n

YERL\u0130 A\u015eININ FORM\u00dcLDEN \u00dcRET\u0130ME YOLCULU\u011eU<\/strong><\/p>\n

A\u015f\u0131 \u00e7al\u0131\u015fmas\u0131nda kullan\u0131lan vir\u00fcs, Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131\u2019ndan temin edilerek a\u015f\u0131 geli\u015ftirme \u00e7al\u0131\u015fmalar\u0131na ba\u015fland\u0131. \u00d6zel dolaplarda eksi 86 derecede saklanan vir\u00fcs bankalar\u0131, daha sonra y\u00fcksek g\u00fcvenlikli kabinlerde \u00e7\u00f6z\u00fclerek \u00f6zel h\u00fccre hatlar\u0131yla \u00e7al\u0131\u015f\u0131ld\u0131 ve a\u015f\u0131n\u0131n ilk form\u00fclasyonu olu\u015fturuldu. Bu form\u00fcl, farkl\u0131 proseslerle \u00f6nce birka\u00e7 litre hacme ula\u015ft\u0131r\u0131ld\u0131; pre-klinik \u00e7al\u0131\u015fmalarda hayvan deneylerinde kullan\u0131ld\u0131. Ana laboratuvardaki reakt\u00f6rde ise \u00fcretim hacmi art\u0131r\u0131larak Faz 1 g\u00f6n\u00fcll\u00fc denemelerinde kullan\u0131lacak dozda \u00fcretim sa\u011fland\u0131. Denemelerde kullan\u0131lacak 1000 dozluk enjeksiyonlar\u0131n dolumu da bu tesislerde ger\u00e7ekle\u015ftirildi. Bu reakt\u00f6rler sayesinde ba\u015flang\u0131\u00e7taki birka\u00e7 litrelik hacimler, ihtiyaca g\u00f6re gerekirse ayda 20 milyon dozluk \u00fcretim kapasitesine kadar \u00e7\u0131k\u0131labiliyor.<\/p>\n","protected":false},"excerpt":{"rendered":"

Sa\u011fl\u0131k Bakan\u0131 Dr. Fahrettin Koca, ilk kez ge\u00e7ti\u011fimiz hafta Tekirda\u011f\u2019daki Ko\u00e7ak Farma Tesisleri\u2019nde, Covid-19 yerli a\u015f\u0131 \u00e7al\u0131\u015fmalar\u0131n\u0131n y\u00fcr\u00fct\u00fcld\u00fc\u011f\u00fc laboratuvarda incelemede bulunarak Cumhurba\u015fkan\u0131 Recep Tayyip Erdo\u011fan ile g\u00f6r\u00fcnt\u00fcl\u00fc g\u00f6r\u00fc\u015fme yapm\u0131\u015f ve \u00e7al\u0131\u015fmalara ili\u015fkin bilgi vermi\u015fti.Bakan Koca, daha sonra m\u00fcjdeyi vererek Faz 1 denemelerine 44 g\u00f6n\u00fcll\u00fc \u00fczerinde ba\u015flanaca\u011f\u0131n\u0131 a\u00e7\u0131klam\u0131\u015ft\u0131. Yar\u0131m as\u0131rl\u0131k yerli firma Ko\u00e7ak Farma\u2019n\u0131n Genel M\u00fcd\u00fcr\u00fc ve CEO’su \u0130\u00e7 Hastal\u0131klar\u0131 Uzman\u0131 Dr. Hakan Ko\u00e7ak, pre-klinik yani hayvan deneyleri tamamlanan ve art\u0131k insanlar \u00fczerinde klinik ara\u015ft\u0131rmalar\u0131n ba\u015flat\u0131ld\u0131\u011f\u0131 Faz 1 a\u015famas\u0131na gelen yerli a\u015f\u0131yla ilgili merak edilenleri anlatt\u0131.Y\u00fcksek g\u00fcvenlikli BSL-3 laboratuvar\u0131na sahip Ko\u00e7ak Farma\u2019n\u0131n \u00c7erkezk\u00f6y\u2019deki 140 bin metrekarelik tesislerinde, pandemi d\u00f6neminde ikinci bir giri\u015fim daha yap\u0131ld\u0131 ve Covid a\u015f\u0131s\u0131n\u0131n \u00fcretimi i\u00e7in birka\u00e7 ay i\u00e7inde yakla\u015f\u0131k 20 milyon euro\u2019luk yat\u0131r\u0131mla ikinci bir BSL-3 laboratuvar\u0131 daha kurularak akreditasyonu tamamland\u0131. Dr. Ko\u00e7ak, laboratuvarlar\u0131n, geli\u015ftirilen di\u011fer yerli a\u015f\u0131lar ve talep olursa yabanc\u0131 a\u015f\u0131lar\u0131n \u00fcretimini de yapabilecek kapasiteye sahip oldu\u011funu vurgulad\u0131.<\/p>\n","protected":false},"author":1,"featured_media":974,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,13],"tags":[421,424,422,423,425],"class_list":["post-973","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-manset","category-saglik","tag-asi","tag-doz","tag-gonullu","tag-kocak","tag-once"],"_links":{"self":[{"href":"https:\/\/balikesirobjektif.com\/index.php\/wp-json\/wp\/v2\/posts\/973","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/balikesirobjektif.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/balikesirobjektif.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/balikesirobjektif.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/balikesirobjektif.com\/index.php\/wp-json\/wp\/v2\/comments?post=973"}],"version-history":[{"count":2,"href":"https:\/\/balikesirobjektif.com\/index.php\/wp-json\/wp\/v2\/posts\/973\/revisions"}],"predecessor-version":[{"id":1156,"href":"https:\/\/balikesirobjektif.com\/index.php\/wp-json\/wp\/v2\/posts\/973\/revisions\/1156"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/balikesirobjektif.com\/index.php\/wp-json\/wp\/v2\/media\/974"}],"wp:attachment":[{"href":"https:\/\/balikesirobjektif.com\/index.php\/wp-json\/wp\/v2\/media?parent=973"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/balikesirobjektif.com\/index.php\/wp-json\/wp\/v2\/categories?post=973"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/balikesirobjektif.com\/index.php\/wp-json\/wp\/v2\/tags?post=973"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}